Showing results (1-10 of 263) with videos related to
Sort By:
Pageof 27
Cancer Treatment and Research|February 7, 2015
Management of diffuse large B-cell lymphoma (DLBCL)Boris Kubuschok, Gerhard Held, Michael PfreundschuhInternational Journal of Cancer|March 22, 2007
Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUSKlaus-Dieter Preuss, Gerhard Held, Boris Kubuschok, et al.Annals of Hematology|February 25, 2009
Analysis of the antibody repertoire of patients with mantle cell lymphoma directed against mantle cell lymphoma-associated antigensCarsten Zwick, Klaus-Dieter Preuss, Boris Kubuschok, et al.Cancer Immunology, Immunotherapy : CII|April 27, 2013
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumorsFrank Neumann, Dominic Kaddu-Mulindwa, Thomas Widmann, et al.Journal of Cancer Research and Clinical Oncology|February 24, 2009
Spontaneous high-titered IgG antibody responses against BCL-2 in patients with aggressive lymphomasCarsten Zwick, Gerhard Held, Vera Hammermeister, et al.Expert Review of Anticancer Therapy|August 24, 2006
Rituximab for the treatment of diffuse large B-cell lymphomasGerhard Held, Viola Pöschel, Michael PfreundschuhHuman Gene Therapy|September 13, 2012
Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trialBoris Kubuschok, Michael Pfreundschuh, Rainer Breit, et al.Seminars in Hematology|October 10, 2006
Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomasGerhard Held, Joerg Schubert, Marcel Reiser, et al.Cancer Immunology, Immunotherapy : CII|January 28, 2004
Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypesFrank Neumann, Claudia Wagner, Boris Kubuschok, et al.The Journal of Clinical Investigation|December 9, 2014
Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factorKlaus-Dieter Preuss, Michael Pfreundschuh, Martin Weigert, et al.Pageof 27